Drugs / GX-E2
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02291991 | Nov 2014 → Jan 2015 | — | Genexine, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01363934 | Jun 2011 → Jul 2012 | — | Green Cross Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02044653 | Apr 2014 → Apr 2017 | anemia, chronic kidney disease | Genexine, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GX-E2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02291991 ↗ |
| Known as | GC1113 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01363934 ↗ |
| Route | Intravenous | “once intravenously” NCT01363934 ↗ |